GERNGeron Corporation

Geron stock has recovered over the past year but is still sitting on a steep decline over three years, while the valuation checks currently lean toward the shares looking inexpensive relative to fundamentals. Over the last three years, Geron has delivered a return of about 51% in decline, which signals that long term holders have faced significant capital pressure despite more recent gains. Expectations for Geron's ability to convert its pipeline into sustainable cash flows can support the...

Why Geron Stock Is Back in Focus After Fresh Guidance Geron (GERN) has drawn fresh attention after issuing 2026 earnings guidance tied to RYTELO net product revenue and releasing second quarter and half year 2026 results on 5 August, including updated revenue and net loss figures. See our latest analysis for Geron. Geron’s latest guidance and earnings update landed alongside a share price of $1.48, with a 7 day share price return of 14.73% and a 1 year total shareholder return of 15.62%. The...

In the second quarter of 2026, Geron Corporation reported revenue of US$57.48 million versus US$49.04 million a year earlier, a net loss of US$16.68 million, first-half revenue of US$109.32 million, and a reduced first-half net loss of US$20.32 million, while also filing a US$6.03 million common stock shelf registration for 4,500,000 shares tied to an ESOP. Investors now have an initial full-year 2026 view on RYTELO, with Geron guiding to net product revenue between US$220 million and US$240...

RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.

Geron Corp (GERN) reports 17% year-over-year net revenue growth, raises full-year guidance, and progresses regulatory discussions for its IMPACT MF trial.

Moby summary of Geron Corporation's Q2 2026 earnings call

Geron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndromes, or MDS. Chief Executive Officer Harout Semerjian said first-half net

Geron (GERN) delivered earnings and revenue surprises of -100.00% and +4.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Precigen (PGEN) delivered earnings and revenue surprises of +350.00% and +97.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) delivered earnings and revenue surprises of +42.90% and +11.74%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Geron Corporation (NASDAQ:GERN) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On June 18, 2026, Geron Corporation (NASDAQ:GERN) reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees. The grants were made as an inducement material […]